Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma by Wade, Ros et al.
This is a repository copy of Methods for selecting the best evidence to inform a NICE 
technology appraisal on selective internal radiation therapies for hepatocellular carcinoma.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/164554/
Version: Published Version
Article:
Wade, Ros orcid.org/0000-0002-8666-8110, Sharif, Sahar, Harden, Melissa et al. (4 more 
authors) (2020) Methods for selecting the best evidence to inform a NICE technology 
appraisal on selective internal radiation therapies for hepatocellular carcinoma. Systematic
Reviews. 184. ISSN 2046-4053 
https://doi.org/10.1186/s13643-020-01447-x
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH Open Access
Methods for selecting the best evidence to
inform a NICE technology appraisal on
selective internal radiation therapies for
hepatocellular carcinoma
Ros Wade* , Sahar Sharif-Hurst, Melissa Harden, Matthew Walton, Lindsay Claxton, Robert Hodgson and
Alison Eastwood
Abstract
Background: Systematic reviews of medical devices are particularly challenging as the quality of evidence tends to
be more limited than evidence on pharmaceutical products. This article describes the methods used to identify,
select and critically appraise the best available evidence on selective internal radiation therapy devices for treating
hepatocellular carcinoma, to inform a technology appraisal for the National Institute for Health and Care Excellence.
Methods: A comprehensive search of ten medical databases and six grey literature sources was undertaken to
identify studies of three devices (TheraSphere®, SIR-Spheres® and QuiremSpheres®) for treating hepatocellular
carcinoma. The large evidence base was scoped before deciding what level of evidence to include for data
extraction and critical appraisal. The methodological quality of the included studies was assessed using criteria
relevant to each study design.
Results: Electronic searches identified 4755 records; over 1000 met eligibility criteria after screening titles and
abstracts. A hierarchical process was used to scope these records, prioritising comparative studies over non-
comparative studies, where available. One hundred ninety-four full papers were ordered; 64 met the eligibility
criteria. For each intervention, studies were prioritised by study design and applicability to current UK practice,
resulting in 20 studies subjected to critical appraisal and data extraction. Only two trials had a low overall risk of
bias. In view of the poor quality of the research evidence, our technology appraisal focused on the two higher
quality trials, including a thorough critique of their reliability and generalisability to current UK practice. The 18
poorer quality studies were briefly summarised; many were very small and results were often contradictory. No
definitive conclusions could be drawn from the poorer quality research evidence available.
Conclusions: A systematic, pragmatic process was used to select and critically appraise the vast quantity of
research evidence available in order to present the most reliable evidence on which to develop recommendations.
Systematic review registration: PROSPERO CRD42019128383.
Keywords: Technology appraisal, Systematic review, Study selection, Critical appraisal, Selective internal radiation
therapy, Hepatocellular carcinoma
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: ros.wade@york.ac.uk
Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
Wade et al. Systematic Reviews           (2020) 9:184 
https://doi.org/10.1186/s13643-020-01447-x
Background
The National Institute for Health and Care Excellence
(NICE) uses the best available evidence to develop rec-
ommendations that guide decisions in health, public
health and social care. Technology appraisals assess the
clinical and cost-effectiveness of health technologies, in-
cluding pharmaceutical products, procedures and de-
vices, to develop recommendations on their use within
the NHS. This ensures that all patients have equitable
access to the most clinically and cost-effective treat-
ments available. Single technology appraisals assess a
single drug or treatment, whereas multiple technology
appraisals assess several drugs or treatments used for the
same condition [1].
The process of undertaking a NICE technology ap-
praisal involves identifying relevant evidence to inform
UK practice, relating to a specific scope issued by NICE.
Systematic searches aim to identify all relevant evidence
to inform indirect comparisons and economic analyses
to estimate the relative clinical and cost-effectiveness of
the technologies being appraised. The highest quality
evidence contributes directly to the formal assessment of
clinical and cost-effectiveness, whilst lower quality evi-
dence is presented as supporting evidence within the ap-
praisal, hence the requirement for prioritisation of the
evidence identified.
This article describes the methods used to identify, se-
lect and critically appraise the best available clinical ef-
fectiveness evidence in a systematic review conducted
for a multiple technology appraisal of selective internal
radiation therapies (SIRT) for treating hepatocellular
carcinoma (HCC). Recommendations on the use of SIRT
within the NHS are being developed on the basis of this
appraisal, which also included an economic model, in-
formed by the clinical effectiveness review, to assess the
cost-effectiveness of SIRT. The NHS is legally obliged to
fund and resource medicines and treatments recom-
mended by NICE’s technology appraisals.
HCC is the most common type of primary liver can-
cer. The majority of HCCs are associated with a known
underlying aetiology; in the UK, the underlying aetiology
is commonly alcohol-related liver disease or non-
alcoholic fatty liver disease, whilst in non-Western popu-
lations, viral hepatitis infection is the primary cause of
HCC [2]. Clinical management of HCC is complex,
owing to the reduced liver function of patients resulting
from both the underlying liver disease and the growing
tumour. The Barcelona Clinic Liver Cancer (BCLC) sta-
ging system is used to establish prognosis and enable the
selection of appropriate treatment based on the combin-
ation of tumour burden, liver function and performance
status. Patients are classified into five stages: (0) very
early stage, (A) early stage, (B) intermediate stage, (C)
advanced stage and (D) terminal stage [3].
The primary aim of therapy in patients with very early or
early stage HCC is typically curative, including surgery (re-
section or transplant) or ablation. Conventional transarter-
ial therapies, which deliver an embolising agent (alone or in
combination with chemotherapy) through the hepatic ar-
tery, are the standard of care for patients with intermediate
stage disease, where resection or other curative treatment
modalities are unsuitable. In patients with advanced HCC,
or who have previously failed on conventional transarterial
therapies, the current standard of care is systemic therapy
(sorafenib, lenvatinib or regorafenib). Best supportive care
is offered to patients when conventional transarterial ther-
apies or systemic therapy is not available or appropriate, in-
cluding patients with terminal stage disease.
SIRT deliver radiation directly to liver tumours via micro-
spheres that are injected into the hepatic artery. There are
currently three commercially available SIRT technologies:
TheraSphere®, SIR-Spheres® and QuiremSpheres®. Each of
the SIRT technologies are CE marked class III active med-
ical devices but they differ in their composition. Thera-
Sphere® are glass microspheres containing yttrium-90
radioactive isotopes, SIR-Spheres® are resin microspheres
containing yttrium-90 radioactive isotopes and Quirem-
Spheres® are poly-L-lactic acid microspheres containing
holmium-166 radioactive isotopes. Our clinical advisors
considered that the most likely position for SIRT in the
HCC treatment pathway is for patients with intermediate
or advanced stage HCC as a non-curative treatment option.
In contrast to pharmaceutical product development,
where medicines have to be rigorously evaluated for
safety and efficacy (regulated by the European Medicines
Agency in Europe and the Food and Drug Administra-
tion in the USA) before they can be placed on the mar-
ket, medical devices undergo a conformity assessment to
demonstrate that they are safe and perform as intended.
Manufacturers can place a CE (Conformité Européenne)
mark on a medical device once it has passed a conform-
ity assessment. Evidence requirements for CE markings
are limited and focussed primarily upon safety; medical
devices are often evaluated using non-randomised stud-
ies or small single centre trials [4]. Therefore, selecting
the best available clinical effectiveness evidence and crit-
ically appraising studies of medical devices can present
particular challenges for systematic reviewers.
This article describes the systematic and pragmatic
methods developed to select and critically appraise the
large body of poor quality research evidence in a system-
atic review conducted for a NICE multiple technology
appraisal of SIRT devices for treating HCC.
Methods
Protocol registration
The research protocol for the full multiple technology
appraisal project was registered on PROSPERO, the
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international prospective register of systematic reviews
in health and social care; registration number
CRD42019128383.
Search strategy
A comprehensive search was undertaken to systematic-
ally identify clinical effectiveness literature. The search
strategy was developed in Ovid MEDLINE by an Infor-
mation Specialist (MH) with input from the review team,
including our clinical advisors (a hepatologist, an inter-
ventional radiologist and a clinical oncologist). The strat-
egy consisted of a set of terms for HCC combined with
terms for SIRT, limited to studies from the year 2000
onwards. The 2000 date limit was applied as scoping
searches had identified controlled studies of SIR-
Spheres® and TheraSphere® published after the year
2000; earlier studies were preliminary uncontrolled stud-
ies with limited value for assessing clinical effectiveness.
In addition, clinical advice confirmed that treatment op-
tions available for patients prior to 2000 were different
from those used in current UK practice. The searches
were not limited by language or study design. The
MEDLINE strategy was adapted for use in all other re-
sources searched.
Ten electronic medical databases and six grey litera-
ture sources were searched on 28 January 2019 (MEDL
INE, EMBASE, Cumulative Index to Nursing & Allied
Health, Science Citation Index, Cochrane Central Regis-
ter of Controlled Trials, Cochrane Database of System-
atic Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment database, NHS Eco-
nomic Evaluations Database, EconLit, ClinicalTrials.gov,
WHO International Clinical Trials Registry portal, EU
Clinical Trials Register, PROSPERO, Conference Pro-
ceedings Citation Index – Science and ProQuest Disser-
tations & Theses A&I). The NICE website and NHS
Evidence were searched for relevant guidelines. Evidence
submissions from the manufacturers/sponsors of the
three SIRT devices and relevant systematic reviews were
also hand-searched to identify further relevant studies.
Clinical advisors were consulted for any additional
studies.
Eligibility criteria
Studies of the selective internal radiation therapies
TheraSphere®, SIR-Spheres® and QuiremSpheres® for pa-
tients with early, intermediate or advanced stage unre-
sectable HCC were included in the review. The
comparator was established clinical management with-
out SIRT, conventional transarterial therapies, systemic
therapy (sorafenib, lenvatinib and regorafenib) or best
supportive care.
Randomised controlled trials (RCTs) were eligible for
inclusion. However, where RCT evidence was lacking for
a particular SIRT device, non-randomised comparative
studies (including retrospective studies) and non-
comparative studies were considered for inclusion. The
evidence was scoped before deciding what level of evi-
dence would be included for data extraction and critical
appraisal.
Study selection
Search results were imported into EndNote® software
and de-duplicated. Studies were initially assessed for
relevance by one reviewer examining titles and abstracts,
with a second reviewer checking 10% of records. Full
manuscripts of any titles/abstracts that appeared relevant
were obtained where possible and the relevance of each
study was assessed independently by two reviewers ac-
cording to the eligibility criteria. Any discrepancies were
resolved through consensus and, where necessary, a
third reviewer was consulted. Relevant foreign language
studies were translated and assessed for inclusion in the
review. Studies available only as abstracts were included
and attempts were made to contact authors for further
data, where necessary.
Critical appraisal
The methodological quality of the included studies was
assessed using criteria relevant to the study design. RCTs
were assessed using the most recent version of the
Cochrane risk of bias tool [5]. Quality assessment tools
for other study designs were developed using relevant
criteria, such as those outlined in CRD’s guidance on
undertaking systematic reviews [6]. Quality assessment
tools were piloted on a small number of studies and re-
fined prior to being used. Quality assessment was under-
taken by one reviewer and independently checked by a
second reviewer. Any disagreements were resolved
through consensus and, where necessary, a third re-
viewer was consulted.
Data synthesis
Characteristics of the included SIRT studies (such as
participant and intervention characteristics, results and
study quality) were tabulated. Pooling of trial data using
meta-analytic techniques was planned, where sufficient
clinically and statistically homogeneous data were avail-
able. Further details of the network meta-analyses and
economic model, that were also presented to NICE as
part of the multiple technology appraisal, are reported in
an HTA report [7].
Results
Prioritisation for full paper screening
The results of the study selection process are presented
in a PRISMA diagram (Fig. 1). A total of 4755 records
were identified by the electronic searches and imported
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into an EndNote® library, after de-duplication between
databases. One reviewer (RW) screened 2615 titles and
abstracts and another reviewer (SS) screened 2617 titles
and abstracts; 477 records (10%) were double screened.
Of the 4755 records, 3670 were excluded based on title
and abstract screening. One thousand and eighty-five re-
cords appeared to meet the eligibility criteria for the
review.
In view of the high number of potentially eligible re-
cords, the evidence was scoped in EndNote® before de-
ciding which studies to order for full paper screening.
Records were coded in terms of the intervention (type of
SIRT and whether the study focussed on the delivery of
SIRT or the work-up of patients prior to SIRT delivery),
the study design (prospective or retrospective, compara-
tive or non-comparative) and the number of HCC pa-
tients included in the study.
Comparative studies were prioritised over non-
comparative studies, which have limited value in com-
paring the clinical and cost-effectiveness of different
technologies. A total of 176 comparative studies ap-
peared to meet the review inclusion criteria; therefore,
all comparative studies were ordered for full paper
screening: 47 RCTs, 26 prospective comparative studies
and 103 retrospective comparative studies. However, it
was clear that there were no comparative studies of the
newer technology QuiremSpheres®; therefore, all studies
that appeared to relate to QuiremSpheres® were ordered
Fig. 1 Flow diagram of the study selection process
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for full paper screening (n = 11). In addition, it was clear
from scoping the Endnote® library that many of the com-
parative studies had small sample sizes (less than 100 pa-
tients). Therefore, large non-comparative studies that
included over 500 patients were also ordered for full
paper screening (n = 6). One final non-comparative
study, in which BCLC subgroups and subsequent treat-
ments were reported and which was considered to be
particularly relevant for the economic model, was also
ordered. Therefore, 194 records were ordered for full
paper screening.
Of the 194 records ordered, 130 were excluded based
on full paper screening and 64 records (55 studies plus 9
associated publications) were considered to be potentially
relevant for inclusion in the clinical effectiveness review.
Hand searching the reference lists of evidence submis-
sions from the manufacturers/sponsors of the three
SIRT devices, relevant systematic reviews and guidelines
identified by the electronic searches did not identify any
additional relevant studies. Clinical advisors were not
aware of any relevant studies not already identified by
the electronic searches.
Prioritisation for data extraction
In view of the high number of studies that met the eligi-
bility criteria for the review and the limited time and re-
source available for reviewing studies, the most reliable
and relevant studies were prioritised for data extraction
and critical appraisal. For each intervention, studies were
first prioritised by study design. There were five RCTs
and two non-randomised prospective comparative stud-
ies of SIR-Spheres® compared with established clinical
management without SIRT. There were two RCTs and
nine non-randomised prospective comparative studies of
TheraSphere® compared with established clinical man-
agement without SIRT. Therefore, 29 retrospective com-
parative studies of SIR-Spheres® or TheraSphere® and
two non-comparative studies were not included for data
extraction, since better quality data were available (see
PRISMA diagram presented in Fig. 1). However, there
were no prospective comparative studies directly com-
paring different SIRT technologies against each other;
therefore, five retrospective comparative studies of SIR-
Spheres® versus TheraSphere® were included. There were
no comparative studies of QuiremSpheres®; therefore,
one small non-comparative study was included, in the
absence of any other research data.
After consultation with our clinical advisors, three
prospective comparative studies that compared SIRT
with therapies that are not applicable to current UK
clinical practice were excluded: hepatic arterial chemo-
therapy (two studies) [8, 9] and 131 I-Lipiodol [10]. One
further prospective comparative study was excluded
because the dose of SIRT used in the study was not ap-
plicable to current UK practice [11].
Twenty of the 55 studies that met the review inclusion
criteria were prioritised for data extraction: seven RCTs,
seven prospective comparative studies, five retrospective
comparative studies and one non-comparative case
series. Basic study characteristics and results are sum-
marised in Additional file 1. Because of the variable
quality of the research evidence available and the differ-
ences between studies, in terms of patient and interven-
tion characteristics and outcomes assessed, pairwise
meta-analysis was not undertaken. A narrative synthesis
of the quantity and quality of evidence on SIRT tech-
nologies was undertaken. Detailed results of the system-
atic review, network meta-analysis and economic model
are reported in an HTA report [7].
Risk of bias
Full risk of bias assessment results are presented in Add-
itional file 2.
Two of the seven included RCTs had a low overall risk
of bias [12, 13], assessed using the most recent version
of the Cochrane risk of bias tool [5]. All other RCTs had
either a high risk of bias [14–16] or some concerns re-
garding bias [17, 18]. There were concerns related to the
randomisation process for each of the five lower quality
RCTs, other concerns related to potential deviations
from the intended interventions, measurement of the
outcome and missing outcome data. All five lower qual-
ity RCTs had very small sample sizes (median 28, range
20 to 45).
All seven prospective comparative studies had a high
risk of bias, assessed using a quality assessment tool de-
veloped specifically for this review [11, 19–24]. In par-
ticular, allocation to treatment groups was either
inadequately described or inappropriate, resulting in
baseline differences in prognostic factors between treat-
ment groups in most studies. Most of the prospective
comparative studies had small sample sizes (median 67,
range 45 to 765).
Four of the five retrospective comparative studies dir-
ectly comparing SIR-Spheres® with TheraSphere® had a
high risk of bias, with baseline differences in prognostic
factors between treatment groups [25–28]. One retro-
spective comparative study had an unclear risk of bias; it
was unclear whether treatment groups were similar at
baseline (due to lack of reporting of patient characteris-
tics for separate treatment groups) or whether missing
outcome data were balanced across treatment groups
[29]. It was unclear whether outcome assessors were
blinded to treatment group in any of the retrospective
studies. All of the retrospective comparative studies had
small sample sizes (median 77, range 17 to 97).
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The small (n = 9) non-comparative case series of Quir-
emSpheres® was considered to be at a high risk of bias; it
was unclear whether the patients included in the study
were representative of those who would be eligible for
SIRT in clinical practice and outcome measures were
not consistently assessed [30].
The majority of research evidence on SIRT devices for
the treatment of HCC was poor quality. Therefore, our
multiple technology appraisal report focused on the two
RCTs with a low overall risk of bias, presenting a de-
tailed description of the results, as well as a thorough
critique of the reliability of the results and their general-
isability to current UK practice. One of the RCTs was
conducted in France, whilst the other was conducted in
the Asia-Pacific region. This has implications for the
generalisability of the results to the UK population. HCC
in European patients is more likely to be caused by alco-
hol or hepatitis C, whereas in Asia, it is more likely to be
caused by hepatitis B. The natural history of these dis-
eases is different, as are the treatment options.
Our report also briefly summarised the results of the
poorer quality studies that were prioritised for data ex-
traction; many of the studies were very small and results
were often contradictory. No definitive conclusions
could be drawn from the poorer quality research evi-
dence available [7]. The network meta-analysis and eco-
nomic model also focussed on the highest quality
evidence, with lower quality studies only considered in
scenario analyses.
Discussion
Good quality research evidence is imperative for deci-
sion makers, such as NICE, to be able to develop clear
recommendations to guide decisions in health, public
health and social care. Medical devices are often evalu-
ated using lower quality research designs, thus reducing
our confidence in the reliability of the findings of the re-
search. Assessing the clinical effectiveness and safety of
medical devices presents particular challenges for sys-
tematic reviewers.
This article describes the methods used to systematic-
ally identify, select and critically appraise the best avail-
able research evidence on the clinical effectiveness of
three SIRT devices (TheraSphere®, SIR-Spheres®, and
QuiremSpheres®) for treating patients with unresectable
early, intermediate or advanced stage HCC.
There is a large body of evidence on the clinical effect-
iveness and safety of SIRT technologies for the treat-
ment of HCC. However, the vast majority of evidence is
very low quality; only seven RCTs were identified, of
which only two had a low risk of bias. The only studies
identified that directly compared the different SIRT de-
vices with each other were small retrospective compara-
tive studies, all of which had a high or unclear risk of
bias. The absence of good quality research evidence
means that decision makers must rely on less robust
findings from poorer quality studies. Most studies identi-
fied were small non-comparative studies, which have
limited value for comparing the clinical and cost-
effectiveness of different technologies. The sheer volume
of small non-comparative data available meant that it
was not possible to review all of the data within the
timeframe available for undertaking this multiple tech-
nology appraisal. The poor quality of the majority of
studies meant that their inclusion in the appraisal would
not have provided reliable evidence for decision makers.
Selecting the best available studies for each SIRT device
highlighted the extremely poor quality of the data avail-
able for QuiremSpheres® in comparison with Thera-
Sphere® and SIR-Spheres®; therefore, no conclusions
could be drawn on the comparative clinical effectiveness
of QuiremSpheres®.
The methods described may be informative to other
research groups undertaking systematic reviews in areas
where there is a large amount of research of uncertain
quality. For this appraisal of multiple technologies for
the treatment of patients with unresectable HCC, com-
parative studies were prioritised over non-comparative
studies in order to present NICE with the most reliable
information upon which to develop recommendations.
Studies were also prioritised in terms of their applicabil-
ity to current UK clinical practice. The most reliable and
representative studies were assessed for bias using cri-
teria relevant to each study design. Our multiple tech-
nology appraisal report focussed on two large RCTs with
a low overall risk of bias, describing the results, a thor-
ough critique of the reliability of each of the trial’s re-
sults and their generalisability to current UK practice.
Poorer quality studies were briefly summarised, many of
which were very small and results were often contradict-
ory. Our methods may be particularly helpful for re-
searchers undertaking systematic reviews of devices,
where the quality of evidence is often poorer. Evidence
requirements for CE markings are more limited than the
requirements for pharmaceutical product development,
in which medicines have to be rigorously evaluated for
safety and efficacy. In addition, this paper may also pro-
vide insight to manufacturers of technologies developing
primary studies of clinical effectiveness and safety.
The key strengths of the review were the compre-
hensive searches of the literature and the systematic
and pragmatic approach used for scoping the vast
quantity of research evidence available, incorporating
both methodological and clinical expertise. The re-
view included a detailed mapping and critical ap-
praisal of the available research evidence on SIRT
devices to ensure that the most reliable evidence was
presented.
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A limitation of the review was the lack of resource to
double screen the titles and abstracts of all 4755 records
in the Endnote® library; only 10% of records were double
screened. However, all full papers retrieved for assess-
ment against inclusion/exclusion criteria were independ-
ently screened by two reviewers. Hand searching of
reference lists of relevant systematic reviews and guide-
lines and evidence submitted by the manufacturers/
sponsors of the three SIRT devices, along with consult-
ation with clinical advisors, did not identify any add-
itional studies. This provides reassurance that no
relevant studies were missed by the search strategy and
screening procedure.
Conclusions
There is a large body of poor quality research evidence
on the clinical effectiveness of SIRT devices for the treat-
ment of HCC. In view of the large body of evidence
available, the most reliable and relevant studies were
prioritised for data extraction and critical appraisal. Our
multiple technology appraisal report focussed on the
RCTs with a low overall risk of bias, briefly summarising
the results of poorer quality studies that were prioritised
for data extraction. The process used to select and critic-
ally appraise the vast quantity of research evidence avail-
able was complex and time consuming, but allowed us
to present NICE with the most reliable evidence on
which to develop recommendations.
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